Strengthening Foundations through Scientific Research and Embracing Digital Intelligence for Development: Bukang Pharmaceutical Successfully Holds 2026 Science & Technology Work Conference and Q1 R&D System Review Meeting

(Source: Buchang Pharmaceuticals)

The year 2026 marks the beginning of China's "15th Five-Year Plan," and the pharmaceutical industry has entered a new stage of development characterized by "intelligence-driven, global synchronization, and differentiated competition."Buchang PharmaceuticalsAnchor "High-Quality Development"、a critical period of transition from 'leading enterprise in the traditional Chinese medicine industry' to 'global health ecosystem builder.' To implement the 'Year of Scientific Research Management',"ImplementProf. Zhao Buchang's handwritten inscription"Uphold Integrity and Innovation, Shoulder Heavy Responsibilities, Develop Medicines for the People, Unfold a Grand Vision, and Live Up to Our Youth"，Full PowerEmpower High-Quality Development of the Company。Technology Management Center collaborates with Technology Development Center,Grandly convened2026 Technology Work Conference and First Quarter Evaluation Meeting of the Research System.

This conference was held onOn March 25th, at Nanyang InternationalConvene，A study seminar was held on March 26.Adopt"Offline Main Venue + Online Tencent Meeting" Dual-Mode Format. The meeting was conducted in three phases: In the first phase, the leaders of the company's board delivered important speeches and directives regarding Buchang Pharmaceuticals' overall R&D work for 2026; in the second phase, reports were given by various management centers and business units within the R&D system.; The third phase: all researchers study the speech of the board leadership in groups, analyze and discuss.Work Reports from 15 Research Leaders: Sharing Experience and Building Consensus。

All personnel from the Buchang Pharmaceuticals research system attended the meeting in person, including General Manager Liu Feng and his team from the Technology Management Center, General Manager Guo Li and his team from the Chairman's Assistant Office for Technology Development Center, General Manager Yang Chun and his team from Beijing Boyuan Runbu Pharmaceutical R&D Co., Ltd., Deputy Director Li Tao from the Beijing Liaison Office, Ma Jiutai and his team from the Xi'an Drug Research and Development Center, General Manager Ren Zhenli and her team from the Shandong Drug Research and Development Center, Quality Vice General Manager Lu Ying and her team from Baoding Tianhao, and R&D Manager Li Xuecai and his team from Jilin Tiancheng.Dean Peng Xiujuan and her team from Shaanxi International Business College，Research Department, Intellectual Property Department; Total148 people.

Mr. Zhao Buchang, Lifetime Honorary Chairman of Buchang Pharmaceuticals, Chairman Zhao Tao, General Manager Zhao Hua of the Logistics Procurement Management Center and team, General Manager Wang Minggeng of the Production Management Center and team, General Manager Wang Yong of the Marketing Department and team, Chief Engineer Zhang Wei of the General Engineer Office and team attended the meeting online. President Zhao Chao, Vice Chairman Wang Yimin, Executive Vice President, and Vice Chairperson Zhao Jing attended in person and all provided important directives on research work.

Chairman Zhao TaoThe work of the Technology Management Center has been affirmed, emphasizing that conducting scientific research must possess a global mindset and global talent. It was pointed out that the board of directors and management need to build a global mindset and decision-making system, attracting global talent with an international perspective.Adhere toDare to Take Risks、Tolerate Failure's scientific research attitude,Empowering Innovative Drug Development through the Capital Market。Finally, all scientific researchers are called uponContinuous learning, continuous超越, achieving ourJohnson & Johnson (China)Dream。

President Chao Zhao with"Where does the strength of technology research and development lie? How do scientific research, product innovation, and technological innovation intersect and integrate in today’s era? Does the research system have a top leader renowned throughout China? How will the five major projects be implemented?" These four questions illuminate the direction and path for transforming into a 'Three Strong' enterprise in scientific research.Spur us to forge ahead bravely——Building a learning organization with a focus on continuous education, aspiring to excellence, and collectively striving to become a technology powerhouse."Three Strong" enterprises and strive hard!

President Zhaocao's Speech

Wang Yimin, Vice Chairman and Executive Vice President"Five Challenges in Project Initiation" and "Promoting the Implementation of Project Responsibility System" — these two dimensions provided guidance for scientific research reform. We will draw on the advanced management experience of multinational corporations to reshape Buchang Pharmaceuticals' scientific research management system. The core objective is to fully activate the vitality and creativity of researchers, mobilize all employees, focus on projects, break through difficulties, and achieve Buchang’s leapfrog development!

Speech by Vice Chairman and Executive Vice President Wang Yimin

Vice Chairman Zhao Jing provided us with an accurate analysis ofThe policy direction and industrial opportunities of the Traditional Chinese Medicine sector in the "15th Five-Year Plan" and the 2026 Government Work Report highlight core policies such as "the pharmaceuticals industry upgrading from a livelihood sector to a national strategic pillar industry" and "Chinese medicines going global becoming the next major national strength at the level of new energy vehicles." These underscore the nation's high regard for the development of the pharmaceuticals industry. As researchers, we should firmly seize this era’s developmental opportunity and harness the driving force of Buchang Pharmaceuticals!

Vice Chairman Zhao Jing's Speech

Subsequently, Liu Feng, General Manager of the Technology Management Center, Guo Li, General Manager of the Technology Development Center, and Yang Chun, General Manager of Beijing Boyuan Runbu Pharmaceutical Research and Development Co., Ltd., respectively gave presentations titled "Strengthening Fundamentals and Expanding Innovations, with Technology as the Priority," "Pathways and Reflections on Improving the Efficiency of Clinical Trials for Innovative Drugs," and "Refinement."·Collaboration·Breakthrough——2026 Q1 Research Summary: Three Work Reports

General Manager Liu Feng proposed:Anchor Country"New '15th Five-Year Plan' Development: Guided by the 12-Word Principle of 'Clear Goals, Strong Organization, and Full Participation,' We Will Fully Implement a New R&D Strategy of 'Improving Existing Assets, Growing New Assets, and Achieving Two-Way Synergy' to Steadily Achieve Buchang's New Goal of 'High-Quality Development.' General Manager Guo Li explained the current status and trends in China’s clinical trial policies, providing new standards, ideas, and pathways for conducting new drug clinical research and improving clinical trial efficiency. General Manager Yang Chun conducted a detailed review of biopharmaceutical R&D work, enabling us to more accurately assess the current state and future direction of projects, clearing the way for subsequent efforts, and laying a solid foundation for the high-quality development of Buchang's biopharmaceuticals."

Chairman Zhao Tao, Wang YiminDeputy Chairman and Executive Vice President, Deputy Chairman Zhao Jing respectively provided commentary and guidance, explicitly proposing that the company should achieve coordinated development of the R&D system by streamlining the management system and implementing a learning committee system, integrating different fields such as traditional Chinese medicine, chemical drugs, biopharmaceuticals, vaccines, and health products."One Chessboard."

Finally, the heads of each center and sector of the scientific research systemAroundVarious Business SegmentsThe“Opportunities and Challenges, Annual Core Tasks and Progress, Management Measures and Pathways, Collaboration Needs and Research Suggestions、And2026TheQ1 Work Report and ImprovementDirection”Six aspectsConducted12 Work Reports.

Among them, the on-site reports were given by 11 speakers: Ma Jiutai, Director of Xi'an Drug Research and Development Center, "Cultivating Project Fertile Ground to Propel Four-Dimensional Advancement"; Ren Zhenli, General Manager of Shandong Drug Research and Development Center, "Anchoring Clinical Value, Refining R&D Pathways – Empowering High-Quality Company Growth through Scientific Research Management"; Lu Ying, Deputy Quality Director of Baoding Tianhao, "Strengthening Foundations, Moving Towards Innovation – 2026 Baoding Tianhao Research Work Report"; Lu Lu, Minister of Intellectual Property Department, "Buchang Pharmaceuticals 2026 Annual Science and Technology Work Conference and First Quarter Evaluation Report of the R&D System"; Guo Jian, Deputy Director of Xi'an Drug Research and Development Center, "Forging Excellent Drugs, Gathering Strength to Open New Horizons"; Sun Yuhong, Technical Director of the Science and Technology Management Center, "Finding Certainty Amid Challenges: 2026 New Drug R&D Value Chain Restructuring and First Quarter Work Report"; Xiao Gongsheng, New Product Director of the Science and Technology Management Center, "Exploring 'Star Path', Insights and Reflections"; Shan Na, Director of the Clinical Research Center, "Focusing Efforts for Quality and Efficiency"; Xu Gang, Director of the Chinese Medicine Resource Development Center, "Upholding the Essence of Traditional Chinese Medicine, Innovating for a New Era, Developing Medicines for the People, Promoting Buchang's Aspirations"; Huang Zhuangzhuang, Director of the Science and Technology Coordination Center, "Pragmatic Actions for Excellence, Continuing a New Chapter of Good Practices – Striving to Open a New Chapter in High-Quality Development of Buchang’s Science and Technology Coordination"; He Juan, Director of the General Office, "Strengthening Pharmaceutical Services, Expanding Innovative Tracks." One online report was delivered by Li Xuecai, General Manager of R&D at Jilin Tiancheng and Tonghua Guhong, titled "Innovation-Driven, Synergy for Long-Term Success – 2026 R&D Center Work Plan and Improvement."

Following the excellent presentations by the respective heads, the board leaders who were online, as well as Vice Chairman Wang Yimin, Executive Vice President, General Manager Liu Feng, General Manager Guo Li, and General Manager Yang Chun, who were present on-site, each conducted inquiries, asked questions, or provided comments and guidance to every presenter. This further clarified Buchang Pharmaceuticals' technological innovation.Strategic Directions and Core Objectives for New Drug Development in 2026Strengthened Buchang Pharmaceuticals' innovation culture and value consensus, boosted the execution motivation and sense of responsibility of Buchang's scientific researchers, and greatly inspired the morale of all researchers.——Buchang Technology, the future is promising!

Head of Each Center and Sector in the Scientific Research SystemWork Report

On March 26, the participants focused on Chairman Zhao Tao and President Zhao Chao,Yimin Wang, Vice Chairman and Executive Vice President，The important speech spirit of Vice Chairman Zhao Jing and four other leaders on scientific research work, as well asThe PPT presentations of 15 scientific research system leaders were studied and discussed in depth. This discussion further consolidated the consensus of all members and gathered innovative momentum.All researchers will put Mr. Zhaobuchang's New Year message into practice through concrete actions:"Uphold Integrity, Innovate to Shoulder Heavy Responsibilities, Research Medicines for the People, and Unfold a Grand Vision, Without Wasting Youth." Fully sprint towards the 2026 scientific research goals, bravely striving to win the "three major battles" and achieve "high-quality development," injecting continuous and powerful scientific research momentum into the strategic vision of "Johnson & Johnson in China, Buchang Pharmaceuticals Worldwide."